4.8 Article

High-performance dendritic contrast agents for X-ray computed tomography imaging using potent tetraiodobenzene derivatives

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 226, Issue -, Pages 258-267

Publisher

ELSEVIER
DOI: 10.1016/j.jconrel.2016.01.036

Keywords

Dendrimers; Computed tomography; In vivo imaging; Iodinated contrast agents; Nanomedicine

Funding

  1. National Research Foundation of Korea - Ministry of Science, ICT and Future Planning [NRF-2015M2A2A6A01044921, NRF-2012M3A9B2028334, KW-2014-PPD-0118, NRF-2010-0008056]
  2. Korea Association of Industry
  3. Academy and Research Institute - Small and Medium Business Administration, Science, and Technology [S1070269]
  4. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare [HI12C0066]
  5. KRIBB Research Initiative Program
  6. National Research Foundation of Korea [2012M3A9B2028334, 2015M2A2A6A01044921] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

The use of computed tomography (CT) for vascular imaging is critical in medical emergencies requiring urgent diagnostic decisions, such as cerebral ischemia and many cardiovascular diseases. Small-molecule iodinated contrast media are often injected intravenously as radiopaque agents during CT imaging to achieve high contrast enhancement of vascular systems. The rapid excretion rate of these agents is overcome by injecting a significantly high dose of iodine, which can have serious side effects. Here we report a simple method to prepare blood-pool contrast agents for CT based on dendrimers for the first time using tetraiodobenzene derivatives as potent radiopaque moieties. Excellent in vivo safety has been demonstrated for these small (13-22nm) unimolecular water-soluble dendritic contrast agents, which exhibit high contrast enhancement in the blood-pool and effectively extend their blood half-lives. Our method is applicable to virtually any scaffold with suitable surface groups and may fulfill the current need for safer, next-generation iodinated CT contrast agents. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available